Organisation paid for research Program year 2024 Source: CMS Open Payments

CMB Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$6,453

89 payments

Through program year 2024, CMB Clinical Trials is reported as receiving $6,453 in research payments, across 89 payments.

By program year

5 rows
Year Kind Amount Payments
2024 Research $210 3
2023 Research $2,805 72
2022 Research $120 2
2020 Research $3,248 11
2019 Research $70 1

Breakdown

Who paid Research payments · program years 2019–2024
  1. Takeda Pharmaceuticals U.S.A., Inc. $3,248 11 payments
  2. Sumitomo Pharma America, Inc. $3,015 75 payments
  3. Sunovion Pharmaceuticals Inc. $120 2 payments
  4. Pfizer Inc. $70 1 payment
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 4, Multicenter, 2-Part Study Composed of A 1-Year Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Active-Comparator, Dose-Optimization Evaluation Followed By A 1-Year Open-Label Evaluation to Assess the Safety and Efficacy of Guanfacine Hydrochloride Prolonged-Release (Spd503) in Children and Adolescents Aged 6 to 17 Years With Attention-Deficit/Hyperactivity Disorder $3,248 11 payments
  2. A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication $2,805 72 payments
  3. A Clinical Study That Will Evaluate How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antipsychotic Medication $210 3 payments
  4. A Clinical Study That Will Evalute How Well SEP-363856 Works and How Safe it is in People With Schizophrenia That Switch to SEP-363856 From Their Current Antisychotic Medication $120 2 payments
  5. 26Week Openlabel Extension Study Evaluating the Safety and Tolerability of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder Most Recent Episode Manic $70 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record